Scott Foraker, A2 Biotherapeutics CEO
December 19, 2022 06:49 AM EST
Financing
Startups
Cell/Gene Tx

Scoop: A2 Bio­ther­a­peu­tics rais­es $62M for sol­id tu­mor cell ther­a­pies

Kyle LaHucik

Senior Reporter

A2 Bio­ther­a­peu­tics has se­cured $62 mil­lion in new fi­nanc­ing — and plans to send two new cell ther­a­pies in­to the clin­ic in the new year with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times